Expertise in
33
conditions

Dr. Susan T. Iannaccone

Neurology | Pediatrics | Pediatric Neurology
5323 Harry Hines Boulevard, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
33
conditions
5323 Harry Hines Boulevard, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Susan Iannaccone is a Neurologist and a Pediatrics provider in Dallas, Texas. Dr. Iannaccone is highly rated in 33 conditions, according to our data. Her top areas of expertise are Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 2, Thymectomy, and Gastrostomy.

Her clinical research consists of co-authoring 72 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Pediatrics
Pediatric Neurology
Licenses
Psychiatry & Neurology in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

5323 Harry Hines Boulevard, Dallas, TX 75390

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Enrollment Status: Recruiting
Publish Date: January 31, 2025
Intervention Type: Drug, Other
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 2
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: April 24, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: September 07, 2022
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Biological
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
Enrollment Status: Completed
Publish Date: August 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: December 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

72 Total Publications

Taking on the Titin: Muscle imaging as a diagnostic marker of biallelic TTN-related myopathy.
Taking on the Titin: Muscle imaging as a diagnostic marker of biallelic TTN-related myopathy.
Journal: Journal of neuromuscular diseases
Published: February 19, 2025
Similar Doctors
Expertise in
28
conditions
Dr. Charuta N. Joshi
Pediatric Neurology | Neurology
Expertise in
28
conditions
Dr. Charuta N. Joshi
Pediatric Neurology | Neurology

Texas Scottish Rite Hospital For Children

2222 Welborn St, 
Dallas, TX 
 (1.7 miles away)
972-449-0540
Experience:
30+ years
Languages Spoken:
English
See accepted insurances

Charuta Joshi is a Pediatric Neurologist and a Neurologist in Dallas, Texas. Dr. Joshi has been practicing medicine for over 30 years is highly rated in 28 conditions, according to our data. Her top areas of expertise are Epilepsy, Seizures, West Syndrome, Epilepsy in Children, and Deep Brain Stimulation.

Expertise in
43
conditions
Dr. Deepa Sirsi
Pediatric Neurology | Pediatrics | Neurology
Expertise in
43
conditions
Dr. Deepa Sirsi
Pediatric Neurology | Pediatrics | Neurology
2350 Stemmons Freeway, 
Dallas, TX 
 (0.4 miles away)
214-456-2768
Languages Spoken:
English
See accepted insurances

Deepa Sirsi is a Pediatric Neurologist and a Pediatrics provider in Dallas, Texas. Dr. Sirsi is highly rated in 43 conditions, according to our data. Her top areas of expertise are Seizures, Epilepsy, Epilepsy in Children, and West Syndrome.

Expertise in
13
conditions
Dr. Berge A. Minassian
Pediatric Neurology | Pediatrics
Expertise in
13
conditions
Dr. Berge A. Minassian
Pediatric Neurology | Pediatrics
5323 Harry Hines Blvd, 
Dallas, TX 
 (0.1 miles away)
214-456-8447
Languages Spoken:
English
See accepted insurances

Berge Minassian is a Pediatric Neurologist and a Pediatrics provider in Dallas, Texas. Dr. Minassian is highly rated in 13 conditions, according to our data. His top areas of expertise are Myoclonic Epilepsy, Epilepsy with Myoclonic-Atonic Seizures, Epilepsy, and Batten Disease.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Iannaccone's expertise for a condition
ConditionClose
View All 25 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile